This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Baseline α–synuclein Seeding Activity and Disease Progression Code
Output Details
Description
Project Title: Baseline α-synuclein seeding activity and Parkinson’s disease progression in the Parkinson's Progression Markers Initiative cohort
Project Overview: Included in this repository is the SAS code used analyze longitudinal clinical and a-synuclein seed amplification assay data from the Parkinson's Progression Markers Initiative (PPMI) and the R code used to create figures.
Dependencies: The data required to run this code can be found in the PPMI Database ([www.ppmi-info.org/access-data-specimens/download-data](http://www.ppmi-info.org/access-data-specimens/download-data); RRID:SCR00_6431). After downloading and curating the data from PPMI, simply update the working directory and file paths to run this code. The following R packages are required to run this code: dplyr, readxl, tableone, writexl, tidyr, VennDiagram, grid, lme4, lmerTest, ggplot2, sjPlot, broom.mixed, patchwork, ggpubr, RColorBrewer, vcd.
Installation: All dependencies will be automatically installed when running this code.
Citation: cff-version 1.2.0
- Type: Software
- Authors:
- Jackson G. Schumacher
- Email: [[email protected]](mailto:[email protected])
- Affiliation: >- Aligning Science Across Parkinson's and Massachusetts General Hospital
- ORCID: [https://orcid.org/0009-0000-4227-4710](https://orcid.org/0009-0000-4227-4710)
- Xinyuan Zhang
- Email: [[email protected]](mailto:[email protected])
- Affiliation: Harvard Medical School
- ORCID: [https://orcid.org/0000-0002-2974-8392](https://orcid.org/0000-0002-2974-8392)
- License: CC-BY-4.0
Acknowledgements: This research was funded in part by Aligning Science Across Parkinson's No. ASAP-237603 through the Michael J. Fox Foundation for Parkinson's Research (MJFF) and by the National Institute of Health through the National Institute of Neurological Disorders and Stroke grants R01NS102735 and 5R01NS126260. The authors would like to thank PPMI – a public-private partnership – funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, Abbvie, AcureX, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's, AskBio, Avid Radiopharmaceuticals, BIAL, BioArctic, Biogen, Biohaven, BioLegend, BlueRock Therapeutics, Bristol-Myers Squibb, Calico Labs, Capsida Biotherapeutics, Celgene, Cerevel Therapeutics, Coave Therapeutics, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Golub Capital, Handl Therapeutics, Insitro, Jazz Pharmaceuticals, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Meso Scale Discovery, Mission Therapeutics, Neurocrine Biosciences, Neuron23, Neuropore, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi, Servier, Sun Pharma Advanced Research Company, Takeda, Teva, UCB, Vanqua Bio, Verily, Voyager Therapeutics, the Weston Family Foundation and Yumanity Therapeutics.
Identifier (DOI)
10.5281/zenodo.14902493